Gene, Cell and Tissue

Published by: Kowsar

PARP Inhibitors and DNA Repair: A Novel Beneficial Approach for Targeting Synthetic Lethal Tumor Cells

Ramin Saravani 1 , * , Saman Sargazi 2 , Hamid-Reza Galavi 1 and Sadegh Zarei 2
Authors Information
1 Cellular and Molecular Research Center and Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Clinical Biochemistry, School of Medicine, Yazd University of Medical Sciences, Yazd, Iran
Article information
  • Gene, Cell and Tissue: July 2017, 4 (3); e62160
  • Published Online: July 31, 2017
  • Article Type: Letter
  • Received: May 1, 2017
  • Accepted: June 13, 2017
  • DOI: 10.5812/gct.62160

To Cite: Saravani R, Sargazi S, Galavi H, Zarei S. PARP Inhibitors and DNA Repair: A Novel Beneficial Approach for Targeting Synthetic Lethal Tumor Cells, Gene Cell Tissue. 2017 ; 4(3):e62160. doi: 10.5812/gct.62160.

Copyright © 2017, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Oconnor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene. 2007;26(56):7816-24. doi: 10.1038/sj.onc.1210879. [PubMed: 18066095].
  • 2. Kaelin WJ. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689-98. doi: 10.1038/nrc1691. [PubMed: 16110319].
  • 3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-7. doi: 10.1038/nature03443. [PubMed: 15829966].
  • 4. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21. doi: 10.1038/nature03445. [PubMed: 15829967].
  • 5. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287-94. doi: 10.1038/nature10760. [PubMed: 22258607].
  • 6. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064-8. [PubMed: 9353181].
  • 7. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta A, Valenzuela MT, Matinez-Romero R, et al. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol. 2007;8:29. doi: 10.1186/1471-2199-8-29. [PubMed: 17459151].
  • 8. Nagaraju G, Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair (Amst). 2007;6(7):1018-31. doi: 10.1016/j.dnarep.2007.02.020. [PubMed: 17379580].
  • 9. Ming M, He YY. PTEN in DNA damage repair. Cancer Lett. 2012;319(2):125-9. doi: 10.1016/j.canlet.2012.01.003. [PubMed: 22266095].
  • 10. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6-7):315-22. doi: 10.1002/emmm.200900041. [PubMed: 20049735].
  • 11. Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010;9(2):347-57. doi: 10.1158/1535-7163.MCT-09-0872. [PubMed: 20124459].
  • 12. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116(22):4578-87. doi: 10.1182/blood-2010-01-265769. [PubMed: 20739657].
  • 13. Sourisseau T, Maniotis D, McCarthy A, Tang C, Lord CJ, Ashworth A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med. 2010;2(4):130-42. doi: 10.1002/emmm.201000068. [PubMed: 20373286].
  • 14. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. [PubMed: 18591545].
  • 15. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293-301. doi: 10.1038/nrc2812. [PubMed: 20200537].
  • 16. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem. 2010;53(12):4561-84. doi: 10.1021/jm100012m. [PubMed: 20364863].
  • 17. Damours D, Desnoyers S, Dsilva I, Poirier GG. Poly, (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J. 1999;342 ( Pt 2):249-68. [PubMed: 10455009].
  • 18. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair. Nature. 2015;518(7538):258-62. doi: 10.1038/nature14184. [PubMed: 25642963].
  • 19. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A. Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Nature. 2015;518(7538):254-7. doi: 10.1038/nature14157. [PubMed: 25642960].
  • 20. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196-207. doi: 10.1038/nrm2851. [PubMed: 20177395].
  • 21. Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014;343(6178):1470-5. doi: 10.1126/science.1252230. [PubMed: 24675954].
  • 22. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108(8):3406-11. doi: 10.1073/pnas.1013715108. [PubMed: 21300883].
  • 23. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang H, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170-82. doi: 10.1093/nar/gkl840. [PubMed: 17088286].
  • 24. De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, et al. First in human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol, (American Society of Clinical Oncology). 2013.
  • 25. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. [PubMed: 23810788].
  • 26. Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, et al. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol. 2011;29(15_suppl):3104. doi: 10.1200/jco.2011.29.15_suppl.3104.
  • 27. Huggins Puhalla SL, Beumer JH, Appleman LJ, Tawbi HH, Stoller RG, Lin Y, et al. A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt). J Clin Oncol, (American Society of Clinical Oncology). 2012.
  • 28. Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, et al. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Res. 2016;76(20):6084-94. doi: 10.1158/0008-5472.CAN-15-3240. [PubMed: 27550455].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments